BR112015020587A2 - proteínas de fusão de apelina e suas utilizações - Google Patents

proteínas de fusão de apelina e suas utilizações

Info

Publication number
BR112015020587A2
BR112015020587A2 BR112015020587A BR112015020587A BR112015020587A2 BR 112015020587 A2 BR112015020587 A2 BR 112015020587A2 BR 112015020587 A BR112015020587 A BR 112015020587A BR 112015020587 A BR112015020587 A BR 112015020587A BR 112015020587 A2 BR112015020587 A2 BR 112015020587A2
Authority
BR
Brazil
Prior art keywords
apelin
domain
fusion
fusion proteins
aplnr
Prior art date
Application number
BR112015020587A
Other languages
English (en)
Inventor
Murphy Andrew
Gromada Jesper
Stevis Panayiotis
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112015020587A2 publication Critical patent/BR112015020587A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)

Abstract

resumo patente de invenção: "proteínas de fusão de apelina e suas utilizações". a presente invenção refere-se a uma proteína de fusão ou polipeptídeo compreendendo um peptídeo de apelina fundido a um componente de multimerização. a invenção também fornece uma proteína de fusão ou polipeptídeo compreendendo um peptídeo de apelina fundido com um domínio fc, um fragmento de um domínio fc, ou uma variante de um domínio fc. polipeptídeos de fusão fc de apelina são capazes de se ligarem ao receptor de apelina (aplnr). polipeptídeos de fusão fc de apelina são capazes de ativar o aplnr e ter propriedades farmacoquinéticas melhoradas em comparação com peptídeos de apelina que não estão fundidos com um fc ou um fragmento fc. polipeptídeos de fusão fc de apelina são úteis em doenças e condições relacionadas com a função cardiovascular, diabetes, câncer, obesidade e outras condições relacionadas com a apelina.
BR112015020587A 2013-03-14 2014-03-14 proteínas de fusão de apelina e suas utilizações BR112015020587A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361786172P 2013-03-14 2013-03-14
US201361906567P 2013-11-20 2013-11-20
PCT/US2014/028384 WO2014152955A1 (en) 2013-03-14 2014-03-14 Apelin fusion proteins and uses thereof

Publications (1)

Publication Number Publication Date
BR112015020587A2 true BR112015020587A2 (pt) 2017-10-10

Family

ID=50680161

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015020587A BR112015020587A2 (pt) 2013-03-14 2014-03-14 proteínas de fusão de apelina e suas utilizações

Country Status (16)

Country Link
US (3) US9353163B2 (pt)
EP (1) EP2970415B1 (pt)
JP (1) JP6525951B2 (pt)
KR (1) KR20150127596A (pt)
CN (1) CN105026423A (pt)
AU (1) AU2014236451B2 (pt)
BR (1) BR112015020587A2 (pt)
CA (1) CA2904731A1 (pt)
EA (1) EA201591700A1 (pt)
ES (1) ES2708957T3 (pt)
HK (1) HK1220466A1 (pt)
IL (1) IL240587A0 (pt)
MX (1) MX365551B (pt)
SG (1) SG11201506335YA (pt)
WO (1) WO2014152955A1 (pt)
ZA (1) ZA201505927B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9353163B2 (en) 2013-03-14 2016-05-31 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
AU2014293387B2 (en) 2013-07-25 2017-04-20 Novartis Ag Bioconjugates of synthetic apelin polypeptides
EA201691027A1 (ru) 2013-11-20 2016-12-30 Ридженерон Фармасьютикалз, Инк. Модуляторы aplnr и их применение
GB201407532D0 (en) * 2014-04-29 2014-06-11 Univ Ulster Apelin analogues
CA2951391C (en) 2014-06-10 2021-11-02 Amgen Inc. Apelin polypeptides
ES2854400T3 (es) 2014-10-13 2021-09-21 Univ Maryland Fc-ELA--32 y su uso en el tratamiento de afecciones cardiacas
EP3220961B1 (en) * 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016102648A1 (en) * 2014-12-23 2016-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Metabolically stable apelin analogs in the treatment of disease mediated by the apelin receptor
US10172919B2 (en) 2014-12-29 2019-01-08 Academia Sinica Method for treating influenza A virus infection
EA201791668A1 (ru) 2015-01-23 2017-11-30 Новартис Аг Синтетические конъюгаты апелина с жирной кислотой с улучшенным периодом полураспада
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
EP3600394A4 (en) * 2017-03-22 2021-04-14 Research Corporation Technologies, Inc. MANIPULATED STABLE CH2-POLYPEPTIDES
EP3604538A4 (en) * 2017-03-29 2020-12-30 University of Miyazaki LONG-ACTING ADRENOMEDULLINE DERIVATIVE
JP7161494B2 (ja) * 2017-05-06 2022-10-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ａｐｌｎｒアンタゴニストおよびｖｅｇｆ阻害剤によって眼疾患を治療する方法
CN109771634A (zh) * 2017-07-11 2019-05-21 南华大学 含有apelin 12环肽的药物组合物及用途
US11365242B2 (en) * 2017-08-24 2022-06-21 Phanes Therapeutics, Inc. Anti-apelin antibodies and uses thereof
GB201805675D0 (en) 2018-04-05 2018-05-23 Davenport Anthony Peter Compounds For Use As Apelin Receptor Antagonists
CN110655577A (zh) * 2018-06-13 2020-01-07 鸿运华宁（杭州）生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
JP2023531368A (ja) * 2020-06-25 2023-07-24 グリックニック インコーポレイテッド Ａｃｅ２－ｆｃ融合タンパク質および使用方法
CN112546198B (zh) * 2020-12-17 2022-03-25 温州医科大学慈溪生物医药研究院 一种用于治疗脑中风和急性脑梗的药物组合物
CN113648418B (zh) * 2021-05-08 2022-08-05 南方医科大学 Apelin-APJ抑制剂在制备治疗血睾屏障损伤药物中的应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP3070763B2 (ja) 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US5972650A (en) 1997-06-26 1999-10-26 Brigham And Women's Hospital Tetracycline repressor regulated mammalian cell transcription and viral replication switch
AU1685499A (en) 1997-12-24 1999-07-19 Takeda Chemical Industries Ltd. Polypeptide, their production and use
US6475718B2 (en) 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
JP2003514552A (ja) * 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
WO2002036762A1 (fr) * 2000-10-30 2002-05-10 Takeda Chemical Industries, Ltd. Procede de fabrication de peptides
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
CA2434802C (en) 2001-01-16 2013-05-28 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
DE10138569A1 (de) 2001-08-06 2003-04-30 Bayer Ag Regulation des APJ-Rezeptors
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
ATE471722T1 (de) 2003-03-12 2010-07-15 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
US7450586B2 (en) * 2003-07-22 2008-11-11 Motorola, Inc. Network header compression arrangement
AU2005207960A1 (en) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-Fc (FSH-Fc) fusion proteins for the treatment of infertility
WO2005106493A1 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj)
US20060045880A1 (en) 2004-08-23 2006-03-02 Krieg Paul A Methods for modulating angiogenesis and apoptosis with apelin compositions
WO2006076736A2 (en) 2005-01-14 2006-07-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis, lymphangiogenesis, and apoptosis with apelin compositions
US8673848B2 (en) * 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
JPWO2007072980A1 (ja) 2005-12-20 2009-06-04 武田薬品工業株式会社 アペリンの新規用途
ES2415604T3 (es) * 2007-05-30 2013-07-26 Postech Academy-Industry- Foundation Proteínas de fusión de inmunoglobulina
PL2150617T3 (pl) 2007-06-04 2015-04-30 Regeneron Pharma Wzmocniona ekspresja i regiony stabilności
JP2012507523A (ja) 2008-11-04 2012-03-29 アンカー セラピューティクス，インコーポレイテッド Ａｐｊ受容体化合物
CA2753287A1 (en) * 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
US8946382B2 (en) 2009-02-27 2015-02-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Apelin peptides and methods of use
US9174428B2 (en) * 2009-08-10 2015-11-03 Corning Incorporated Roll mechanics for enabling printed electronics
KR101934923B1 (ko) 2009-11-02 2019-04-10 유니버시티 오브 워싱톤 스루 이츠 센터 포 커머셜리제이션 치료학적 뉴클레아제 조성물 및 방법
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
AU2011283694B2 (en) * 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
US8881594B2 (en) * 2011-03-06 2014-11-11 Alexander Henry Slocum Tapered spiral bellows pressure sensor
SI3045183T1 (sl) 2011-03-11 2018-11-30 Genzyme Corporation Pegiliran Apelin in njegove uporabe
EP2692352A4 (en) 2011-03-31 2014-12-24 Shiseido Co Ltd MEANS FOR SUPPRESSING HEADWALLS
US9156911B2 (en) 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
WO2013078463A1 (en) * 2011-11-23 2013-05-30 Quarkstar Llc Light-emitting devices providing asymmetrical propagation of light
CN102516393B (zh) 2011-11-30 2017-03-15 北京康明百奥新药研发有限公司 胰岛素模拟肽融合蛋白和突变体及其应用
CN102675470B (zh) * 2012-04-01 2015-06-17 江苏省弗泰生物科技有限公司 SCF-Fc融合蛋白
WO2014099984A1 (en) 2012-12-20 2014-06-26 Amgen Inc. Apj receptor agonists and uses thereof
US9353163B2 (en) 2013-03-14 2016-05-31 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
EA201691027A1 (ru) 2013-11-20 2016-12-30 Ридженерон Фармасьютикалз, Инк. Модуляторы aplnr и их применение

Also Published As

Publication number Publication date
JP6525951B2 (ja) 2019-06-05
MX365551B (es) 2019-06-07
AU2014236451A1 (en) 2015-10-15
JP2016513733A (ja) 2016-05-16
CA2904731A1 (en) 2014-09-25
WO2014152955A1 (en) 2014-09-25
KR20150127596A (ko) 2015-11-17
SG11201506335YA (en) 2015-09-29
US20180030099A1 (en) 2018-02-01
ZA201505927B (en) 2017-03-29
IL240587A0 (en) 2015-09-24
EP2970415B1 (en) 2018-12-19
EP2970415A1 (en) 2016-01-20
AU2014236451B2 (en) 2018-08-09
US9353163B2 (en) 2016-05-31
CN105026423A (zh) 2015-11-04
MX2015011350A (es) 2016-01-15
EA201591700A1 (ru) 2015-12-30
ES2708957T3 (es) 2019-04-12
US20160237130A1 (en) 2016-08-18
US9751921B2 (en) 2017-09-05
HK1220466A1 (zh) 2017-05-05
US20140275489A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
BR112015020587A2 (pt) proteínas de fusão de apelina e suas utilizações
BR112016016411A2 (pt) VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2022008013A (es) Estabilizacion de polipeptidos que contienen fragmentos cristalizables.
PL397167A1 (pl) Przeciwnowotworowe bialko fuzyjne
WO2013184938A3 (en) Fusion polypeptides comprising mucin-domain polypeptide linkers
BR112016016416A2 (pt) VARIANTES DE REGIÕES-"Fc" COM 'FcRn' MODIFICADAS E PROPRIEDADES DE LIGAÇÃO DE PROTEÍNA "A" MANTIDAS
WO2012170438A3 (en) HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING β-KLOTHO AND AN FGF RECEPTOR
EA201792245A1 (ru) Биоконъюгаты и их применения
MX2022015847A (es) Proteinas de union a cd123 y composiciones y metodos relacionados.
WO2016161244A3 (en) Methods and compositions related to gpcr agonist polypeptides
EP3670534A3 (en) Human fgf receptor and beta-klotho binding proteins
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
EA201290722A1 (ru) Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
AR094149A1 (es) Proteinas multifuncion que comprenden chm de clase i multivalente unido mediante disulfuro
EP2504360A4 (en) FC MONOMER ANTIBODY
WO2015175874A3 (en) Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
EA201791238A1 (ru) Способы и композиции, в которых используются варианты полипептидов klotho
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
UA117493C2 (uk) Гібридна конструкція, що включає антигенсполучний фрагмент, специфічний до сироваткового альбуміну, й ефекторний компонент, та способи її одержання
BR112017001463A2 (pt) célula hospedeira melhorada para produzir proteínas
MX2020002977A (es) Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos.
MX2013014008A (es) Anticuerpo que se aglutina a un polipeptido del transportador a1 del casete de aglutinacion a adenosin trifosfato (atp) (abca 1).
LV15035A (lv) Rekombinēta himēriska polipeptīda, kas satur melanokortīna otrā tipa receptoru (MC2R) un melanokortīnu receptoru palīgproteīnu (MRAP), kDNS secības, un tās izmantošana aktīvo vielu testēšanai un terapeitiskiem mērķiem
TH177202A (th) โพลีเปปไทด์ IL-22 และฟิวชันโปรตีน IL-22 Fc และวิธีการใช้

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements